In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx Inc (APTX). The company’s shares closed yesterday at $19.99.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.4% and a 48.8% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptinyx Inc with a $40 average price target, which is a 100.1% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $40 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.25 and a one-year low of $17.35. Currently, Aptinyx Inc has an average volume of 118.9K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It is discovering and developing transformative therapies for disorders of the brain and nervous system. The company was founded by Norbert G. Riedel and Joseph R. Moskal and is headquartered in Evanston, IL.
